Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 0.61 |
| ▸ | MMP13 | P45452 | 20/20 | 0.61 |
| ▸ | ADAM17 | P78536 | 20/20 | 0.61 |
| ▸ | MMP9 | P14780 | 16/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658398 | 0.92 | MMP1 (0.74) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL8266848 | 0.92 | MMP1 (0.62) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL5654712 | 0.91 | MMP13 (0.60) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL5655618 | 0.90 | MMP1 (0.62) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL3940219 | 0.84 | MMP13 (0.85) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL3939462 | 0.83 | MMP13 (0.73) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL3950441 | 0.83 | MMP13 (0.73) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL5658378 | 0.83 | MMP1 (0.62) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL6609170 | 0.83 | MMP1 (0.82) | MMP1MMP13ADAM17MMP9 | |
| SCHEMBL7421415 | 0.83 | MMP1 (0.63) | MMP1MMP13ADAM17MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-7282496-B2 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-16 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130238-A1 | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors | MMP12, MMP1, SI | MMP1 2/4885MMP13 11/4885ADAM17 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.